By Fineline Cube 
UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has commenced the construction of a new small molecule drug plant in Wuxi, Jiangsu Province. The facility represents a significant investment of USD 475 million and is designed to be AstraZeneca’s latest technology platform.
Facility Specifications
The plant will be equipped with two sets of cutting-edge tablet continuous manufacturing process equipment and seven sustainable pharmaceutical packaging production lines. This state-of-the-art facility underscores AstraZeneca’s commitment to innovation and sustainability in manufacturing.
Expected Timeline
The new plant is expected to become operational in the fourth quarter of 2028. Once operational, it will primarily focus on manufacturing AstraZeneca’s innovative cardiovascular drugs.-Fineline Info & Tech